About Aditi Ganguly
Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do's and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities.
Aditi's fascination with the stock market began in college, where she majored in Economics, while researching The Great Recession for her thesis. After graduating, she began her career handling the content requirements for the mutual fund aggregator Groww. Since then she has become a financial journalist that focuses on writing articles that educate retail investors about the equity markets and the global economy.
Recent Articles By Aditi Ganguly
LiveRamp: Buy, Sell, or Hold?
Shares of data connectivity operator LiveRamp Holdings (RAMP) have been declining over the past couple of months in-part because investors are rotating away from tech stocks and into outdoor stocks. So, will RAMP be able to beat the market trend and maintain its momentum? Read more to find out.
Is Future FinTech Group a Good Chinese Tech Stock to Buy?
Shares of Chinese blockchain financial services company Future Fintech (FTFT) have been among the best performing ADRs over the past year, with triple-digit price gains. However, as China intensifies a crackdown on its domestic fintech industry to curb unchecked growth and assure its sustainability, will FTFT be able to maintain its momentum? Read more to find out.
This is a Great Time to Buy the Dip in Boise Cascade Stock
Infrastructure stock Boise Cascade (BCC) might witness a pullback in the near term owing to rising concerns regarding a fourth wave of COVID-19 and potentially strong opposition to President Biden’s proposed infrastructure bill. So, will the company be able to overcome these challenges and maintain its growth trajectory? Read more to find out.
Nature's Sunshine Products is Up 30% in 2021, Will the Rally Continue?
Nature’s Sunshine Products (NATR) is on track to become one of the biggest names in the health and nutrition space, with increasing earnings potential. However, the stock’s price gains over the past year are now raising concerns about its potential overvaluation. So, will the company be able to keep raising its earnings to deliver adequate returns on investment? Read more to find out.
LightInTheBox Holding Co.: Buy the Dip
Budding Chinese e-commerce retailer LightInTheBox (LITB) has been rapidly increasing its domestic and international operations over the past year, delivering record operational performance. However, amid strained relations between China and the West, will LITB be able to retain its international market share? Read more to find out.
An Under-the-Radar Telehealth Stock to Buy Now
Telehealth software developer NextGen Healthcare (NXGN) is leading the digitization of the healthcare industry with its innovative software designs and services. Despite gaining in the triple-digits in 2020, NXGN stock still looks undervalued given its earnings prospects. Thus, we think NXGN could be a solid addition to one’s portfolio. Let’s take a closer look.
This Surprise Electric Vehicle Stock is Outperforming Tesla and NIO in 2021
The lesser-known Chinese electric mobility scooter manufacturer Niu Technologies (NIU) has been surging lately despite a sharp pullback in the EV stocks owing to a semiconductor chip shortage and asset bubble concerns. Will NIU be able to capitalize on this market slump to increase its market share, or is the stock also due for a trend reversal? Read on to find out.
3 Stocks to Buy for the Genomic Revolution
Cathie Wood has been managing more than $26 billion in assets on which she has delivered robust returns over the past year. Some of her biggest bets on the healthcare industry are placed through Ark Genomic Revolution ETF (ARKG), which has gained more than 180% over the past year. The top holdings in this actively managed ETF include Novartis (NVS), Regeneron Pharmaceuticals (REGN), and Vertex Pharmaceuticals (VRTX). Let’s take a closer look at what Wood sees.
Bank of America Surges 27% YTD: More Upside Left?
Bank of America (BAC) stock has shown resilience amid the Archegos Capital debacle. The stock has soared 28.6% year-to-date as shares of competitor banks declined. However, will BAC be able to side-step long-term ramifications of the biggest margin call in history to deliver solid gains, or will the stock sink in tandem with the overall industry in the near term? Read more to find out.